DiscoverRetina SynthesisRapid Fluid Resolution with Aflibercept 8mg may be Associated with Extended Dosing Intervals in nAMD
Rapid Fluid Resolution with Aflibercept 8mg may be Associated with Extended Dosing Intervals in nAMD

Rapid Fluid Resolution with Aflibercept 8mg may be Associated with Extended Dosing Intervals in nAMD

Update: 2025-09-081
Share

Description

We discuss the observation that resolution of retinal fluid at one month in eyes with nAMD treated with aflibercept 8mg may herald longer duration treatment intervals at week 96 with Michael Stewart,, MD, Knights Templar Professor of Ophthalmology, Mayo Clinic, Jacksonville, Florida.

Comments 
In Channel
8 mg Aflibercept in Diabetic Macular Edema

8 mg Aflibercept in Diabetic Macular Edema

2025-10-0811:18

Subretinal Gene Therapy for Neovascular AMD

Subretinal Gene Therapy for Neovascular AMD

2025-10-0316:26

Does Pegcetacoplan Treatment Affect Dry Macular Degeneration?

Does Pegcetacoplan Treatment Affect Dry Macular Degeneration?

2025-09-2509:01

Rapid Fluid Resolution with Aflibercept 8mg may be Associated with Extended Dosing Intervals in nAMD

Rapid Fluid Resolution with Aflibercept 8mg may be Associated with Extended Dosing Intervals in nAMD

2025-09-0820:58

The Good Days Dilemma - Support for Patient Co-Payments in Retinal Pharmacotherapy

The Good Days Dilemma - Support for Patient Co-Payments in Retinal Pharmacotherapy

2025-08-2812:43

Immediate vs Delayed Treatment of GA with Pegcetacoplan

Immediate vs Delayed Treatment of GA with Pegcetacoplan

2025-08-1917:33

Eyes with both Geographic Atrophy and Neovascular AMD: An IRIS Study

Eyes with both Geographic Atrophy and Neovascular AMD: An IRIS Study

2024-07-1212:07

The Davio 2 Trial for Neovascular AMD

The Davio 2 Trial for Neovascular AMD

2024-05-3113:47

The GALE Extension Study

The GALE Extension Study

2024-05-1715:06

AXPAXLI for Diabetic Retinopathy

AXPAXLI for Diabetic Retinopathy

2024-05-0904:44

NSAIDS in the treatment of Central Serous Chorioretinopathy

NSAIDS in the treatment of Central Serous Chorioretinopathy

2024-04-1814:22

EY-103 a novel Wnt Pathway Agonist for Treatment of DME and neovascular AMD

EY-103 a novel Wnt Pathway Agonist for Treatment of DME and neovascular AMD

2024-04-0421:41

Intravitreal Gene Therapy for neovascular AMD with 4D-150

Intravitreal Gene Therapy for neovascular AMD with 4D-150

2024-03-2813:44

KSI 501 Bispecific Anti-VEGF Biopolymer Treatment of DME

KSI 501 Bispecific Anti-VEGF Biopolymer Treatment of DME

2024-03-2107:38

Retinal Vasculitis Following Pegcetcoplan Therapy of Geographic Atrophy

Retinal Vasculitis Following Pegcetcoplan Therapy of Geographic Atrophy

2024-03-1415:25

High Dose Aflibercept in Severe Diabetic Macular Edema

High Dose Aflibercept in Severe Diabetic Macular Edema

2024-03-0712:22

IL-6 Inhibition in the Treatment of Uveitis Macular Edema

IL-6 Inhibition in the Treatment of Uveitis Macular Edema

2024-02-2909:05

The High Dose Aflibercept DME Trial

The High Dose Aflibercept DME Trial

2024-02-2218:43

The Annexon Geographic Atrophy Trial

The Annexon Geographic Atrophy Trial

2024-02-1511:53

Diagnostics for Retinoblastoma

Diagnostics for Retinoblastoma

2024-02-0819:04

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Rapid Fluid Resolution with Aflibercept 8mg may be Associated with Extended Dosing Intervals in nAMD

Rapid Fluid Resolution with Aflibercept 8mg may be Associated with Extended Dosing Intervals in nAMD

Retina Synthesis